Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 33

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

RNAi-based modulation of IFN-γ signaling in skin

Tang, Qi, Sousa, Jacquelyn, Echeverria, Dimas, Fan, Xueli, Hsueh, Ying-Chao, Afshari, Khashayar, MeHugh, Nicholas, Cooper, David A., Vangjeli, Lorenc, Monopoli, Kathryn, Okamura, Ken, Biscans, Annabelle, Clauss, Adam, Harris, John E., Khvorova, Anastasia · 2022 · Molecular Therapy

Abstract

Aberrant activation of interferon (IFN)-γ signaling plays a key role in several autoimmune skin diseases, including lupus erythematosus, alopecia areata, vitiligo, and lichen planus. Here, we identify fully chemically modified small interfering RNAs (siRNAs) that silence the ligand binding chain of the IFN-γ receptor (IFNGR1), for the modulation of IFN-γ signaling. Conjugating these siRNAs to docosanoic acid (DCA) enables productive delivery to all major skin cell types local to the injection site, with a single dose of injection supporting effective IFNGR1 protein reduction for at least 1 month in mice. In an ex vivo model of IFN-γ signaling, DCA-siRNA efficiently inhibits the induction of IFN-γ-inducible chemokines, CXCL9 and CXCL10, in skin biopsies from the injection site. Our data demonstrate that DCA-siRNAs can be engineered for functional gene silencing in skin and establish a path toward siRNA treatment of autoimmune skin diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2022.04.019

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. Ruffilli, 2019, MIG in cutaneous systemic lupus erythematosus, Clin. Ter, 170, e71
  2. Rork, 2016, Understanding autoimmunity of vitiligo and alopecia areata, Curr. Opin. Pediatr., 28, 463, 10.1097/MOP.0000000000000375 · DOI
  3. Harris, 2012, A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin, J. Invest. Dermatol., 132, 1869, 10.1038/jid.2011.463 · DOI · Paper page
  4. Shao, 2019, IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus, Sci. Transl. Med., 11, eaav7561, 10.1126/scitranslmed.aav7561 · DOI · Paper page
  5. Rashighi, 2014, CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, Sci. Transl. Med., 6, 223ra23, 10.1126/scitranslmed.3007811 · DOI · Paper page
  6. Richmond, 2017, Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease, J. Invest. Dermatol., 137, 350, 10.1016/j.jid.2016.09.016 · DOI · Paper page
  7. Richmond, 2017, CXCR3 depleting antibodies prevent and reverse vitiligo in mice, J. Invest. Dermatol., 137, 982, 10.1016/j.jid.2016.10.048 · DOI · Paper page
  8. van den Boorn, 2009, Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients, J. Invest. Dermatol., 129, 2220, 10.1038/jid.2009.32 · DOI · Paper page
  9. Xing, 2014, Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition, Nat. Med., 20, 1043, 10.1038/nm.3645 · DOI · Paper page
  10. Kennedy Crispin, 2016, Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata, JCI Insight, 1, e89776, 10.1172/jci.insight.89776 · DOI · Paper page
  11. King, 2022, Two phase 3 trials of Baricitinib for alopecia areata, N. Engl. J. Med., 386, 1687, 10.1056/NEJMoa2110343 · DOI · Paper page
  12. Rothstein, 2017, Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib, J. Am. Acad. Dermatol., 76, 1054, 10.1016/j.jaad.2017.02.049 · DOI · Paper page
  13. Rosmarin, 2020, Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial, Lancet, 396, 110, 10.1016/S0140-6736(20)30609-7 · DOI · Paper page
  14. Schwartz, 2017, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Nat. Rev. Drug Discov., 16, 843, 10.1038/nrd.2017.201 · DOI · Paper page
  15. Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888 · DOI · Paper page
  16. Khvorova, 2017, The chemical evolution of oligonucleotide therapies of clinical utility, Nat. Biotechnol., 35, 238, 10.1038/nbt.3765 · DOI · Paper page
  17. Scott, 2020, Givosiran: first approval, Drugs, 80, 335, 10.1007/s40265-020-01269-0 · DOI · Paper page
  18. Scott, 2021, Lumasiran: first approval, Drugs, 81, 277, 10.1007/s40265-020-01463-0 · DOI · Paper page
  19. Lamb, 2021, Inclisiran: first approval, Drugs, 81, 389, 10.1007/s40265-021-01473-6 · DOI · Paper page
  20. Biscans, 2019, Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo, Nucleic Acids Res., 47, 1082, 10.1093/nar/gky1239 · DOI · Paper page
  21. Biscans, 2019, The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo, J. Control Release, 302, 116, 10.1016/j.jconrel.2019.03.028 · DOI
  22. Biscans, 2021, Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles, Mol. Ther., 29, 1382, 10.1016/j.ymthe.2020.12.023 · DOI
  23. Birmingham, 2007, A protocol for designing siRNAs with high functionality and specificity, Nat. Protoc., 2, 2068, 10.1038/nprot.2007.278 · DOI · Paper page
  24. Shmushkovich, 2018, Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs, Nucleic Acids Res., 46, 10905, 10.1093/nar/gky745 · DOI
  25. Moran, 2012, Incyte comes of age with JAK inhibitor approval, Nat. Biotechnol., 30, 3, 10.1038/nbt0112-3 · doi:10.1038/nbt0112-3
  26. Roberts, 2020, Advances in oligonucleotide drug delivery, Nat. Rev. Drug Discov., 19, 673, 10.1038/s41573-020-0075-7 · DOI · Paper page
  27. Valente, 1992, Distribution of interferon-gamma receptor in human tissues, Eur. J. Immunol., 22, 2403, 10.1002/eji.1830220933 · DOI · Paper page
  28. Ivashkiv, 2018, IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy, Nat. Rev. Immunol., 18, 545, 10.1038/s41577-018-0029-z · DOI · Paper page
  29. Seung, 2011, Inhibiting CXCR3-dependent CD8+ T cell trafficking enhances tolerance induction in a mouse model of lung rejection, J. Immunol., 186, 6830, 10.4049/jimmunol.1001049 · DOI
  30. Groom, 2012, CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation, Immunity, 37, 1091, 10.1016/j.immuni.2012.08.016 · DOI · Paper page
  31. Ledford, 2018, Gene-silencing technology gets first drug approval after 20-year wait, Nature, 560, 291, 10.1038/d41586-018-05867-7 · DOI · Paper page
  32. Maouia, 2017, Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients, Pigment Cell Melanoma Res, 30, 259, 10.1111/pcmr.12559 · DOI
  33. Ferguson, 2020, Cell type impacts accessibility of mRNA to silencing by RNA interference, Mol. Ther. Nucleic Acids, 21, 384, 10.1016/j.omtn.2020.06.006 · DOI
  34. Małecka, 2020, Ribosomes clear the way for siRNA targeting, Nat. Struct. Mol. Biol., 27, 775, 10.1038/s41594-020-0495-4 · DOI
  35. Jouanguy, 1997, Infections in IFNGR-1-deficient children, J. Interferon Cytokine Res., 17, 583, 10.1089/jir.1997.17.583 · DOI
  36. Jouanguy, 1999, A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection, Nat. Genet., 21, 370, 10.1038/7701 · DOI · Paper page
  37. van de Vosse, 2017, IFN-γR1 defects: mutation update and description of the IFNGR1 variation database: van de VOSSE and van DISSEL, Hum. Mutat., 38, 1286, 10.1002/humu.23302 · DOI
  38. Horras, 2011, Regulation of hepatocyte fate by interferon-γ, Cytokine Growth Factor Rev., 22, 35, 10.1016/j.cytogfr.2011.01.001 · DOI
  39. Mohammadi, 2021, CC and CXC chemokines play key roles in the development of polyomaviruses related pathological conditions, Virol. J., 18, 111, 10.1186/s12985-021-01582-4 · DOI
  40. Prausnitz, 2017, Engineering microneedle patches for vaccination and drug delivery to skin, Annu. Rev. Chem. Biomol. Eng., 8, 177, 10.1146/annurev-chembioeng-060816-101514 · DOI · Paper page
  41. Tadros, 2020, STAR particles for enhanced topical drug and vaccine delivery, Nat. Med., 26, 341, 10.1038/s41591-020-0787-6 · DOI
  42. Dharamdasani, 2020, Topical delivery of siRNA into skin using ionic liquids, J. Control Release, 323, 475, 10.1016/j.jconrel.2020.04.038 · DOI
  43. Mandal, 2020, Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations, Sci. Adv., 6, eabb6049, 10.1126/sciadv.abb6049 · DOI
  44. Turanov, 2018, RNAi modulation of placental sFLT1 for the treatment of preeclampsia, Nat. Biotechnol., 36, 1164, 10.1038/nbt.4297 · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D. A., Vangjeli, L., Monopoli, K., Okamura, K., Biscans, A., Clauss, A., Harris, J. E., & Khvorova, A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2022-08
Volume
30
Issue
8
Pages
2709-2721
ISSN
1525-0016
Cited by
33
References
11
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.